because optically active a-hydroxyglycine, the constituent containing the asymmetric C-l l, can be neither isolated nor synthesized. The fact that the activity of ll-epimeric mixture of spergualin is about half that of the natural spergualin2) indicates the importance of the configuration at C-l1 for antitumor activity. This report is on the stereochemistry at C-l1 of spergualin analogues, especially 1 5-deoxyspergualin, which is being tested in clinical trials.
Total synthesis of optically active spergualin has been achieved by the acid-catalyzed condensation of glyoxyloylspermidine (IV) with (*S>7-guanidino-3-hydroxyheptanamide (HI) followed by the separation of the ll-epimeric mixture by reversed-phase HPLC.i:) This method is based upon the formation of diastereomers with the participation of the chiral C-15, so it is not useful for the synthesis of optically active 1 5-deoxyspergualin.
Iwasawa et aL reported a method for the preparation of (-)-15-deoxyspergualin from natural spergualin with retention of the configuration of C-l l.3) Thus, the configuration at C-l l of spergualin has been correlated with that of (-)-15-deoxyspergualin.
However, this derivation neither afforded (+)-enantiomers nor was it used to synthesize other analogues with carbon skeletons different from that of spergualin. To explore the relationship between the configuration of C-l l and bioactivity, we synthesized both (-) and (+)-enantiomers of 15-deoxyspergualin, and examined the absolute configuration at C-ll of the bioactive enantiomer.
Chemistry
Synthesis of optically active 15-deoxyspergualin analogues are depicted in Scheme 1. The synthesis required the preparation of optically active and stable intermediates, iV-acyl-O-alkoxyglycine (IX) in place of the unstable a-hydroxyglycine. Condensation of 7-guanidinoheptanamide (V) with glyoxylic acid gave a racemic adduct, JV-(7-guanidinoheptanoyl)-a:-hydroxyglycme (VI). The hydroxyl group of VI was protected by 0-alkylation. Treatment of VI with alcohols in the presence of an acid catalyst gave iV-(7-guanidinoheptanoyl)-a-alkoxyglycine (Vila, R= CH3 ; Vllb, R=CH2C6H5), which was used as the key compound for the optical resolution. Whenbenzyl alcohol was used for protection, the protective group can be removed by hydrogenation with retention of the configuration. Manyattempts to resolve VII failed, including salt formation with optically active bases or acids, diastereomeric ester formation with active alcohols, and selective crystallization. The resolution of VII was achieved by enzymatic hydrolysis of the JV-acyl dipeptide (Villa and VDIb), in which another L-amino acid was attached to VII.
Carboxypeptidase (CPase) P from Penicillium janthinellunfi* or CPase Wfrom wheat bran,5) which are classified as serine (acid) carboxypeptidases [EC 3.4.1 6.1] , catalyze the asymmetric hydrolysis of the peptide bond of VIII to give the (-)-enantiomer of IX. Here, we designated the configuration of the enantiomers ofIX as (-) or (+) in accordance with the optical rotation of the final compound derived from them. These enzymes eliminate the C-terminal amino acid while distinguishing the S-S configuration of the sequent amino acid from the R-S configuration. The remaining R-S isomer of VIII was hydrolyzed by a metallo-CPase such as CPase A from bovine pancreas [EC 3.4.17.1] or CPase B from porcine pancreas [EC 3.4.17.2] to give the (-j-)-enantiomer of IX. Wechose an appropriate CPase according to the terminal amino acid; CPase A was used for the cleavage of neutral amino acids, and CPase B for basic ones. AnyL-amino acid would be suitable for the terminal amino acid, but L-Phe and L-Arg were particularly suitable, because the product IX was readily separated from the substrate VIII containing these amino acids by absorption chromatography or ion-exchange chromatography. Although the optical rotation of the compounds of the a-methoxyglycine series (IXa-Xa-Ha) was of the same sign, optical rotation of the abenzyloxyglycine derivative (IXb) obtained by asymmetric hydrolysis with CPase Wwas dextro-rotatory and the sign was reversed by the introduction of a bulky group to the carboxyl function (Xb and II). Specific rotations of the related compoundsare listed in Table 1 . Thus, the enantiomer derived from CPase P or Whydrolysis gave a (-) series of spergualin analogues, and the other enantiomer gave a (+) series. SEPT. 1987 Scheme 1.
The assumption that the alkoxy group of VIII is sterically equivalent to the alkyl group of normal amino acids led us to deduce that the absolute configuration at C-ll of the (-) series is S.
Condensation of optically active 7-guanidino-a:-alkoxyglycine (IX) with iV-cyanoethylputrescine or partly iV-protected spermidine gave Xa or Xb. Reduction of Xa with NaBH4in the presence of CoCl2 gave optically active 15-deoxy-l l-O-methylspergualin (Ila). Removal of the protective groups of Xb by catalytic hydrogenation gave optically active 1 5-deoxyspergualin (II). The optical purity of each enantiomer of the final products, (Ila and II), was measured by reversed-phase liquid chromatography of their diastereomeric derivatives.
The diastereomers were Cbz : Benzyloxycarbonyl. formed with the help of the chiral reagent, 2,3,4,6-tetra-Oacetyl-/3-D-glucopyranosyl isothiocyanate (GITC), developed by Nimura et al. for the resolution of amino acid enantiomers.5) Analysis showed that the optical purity of each enantiomer of (II and Ila) was high (>98 %).
Bioactivity
The antitumor activity of optically active 15-deoxyspergualin (II) and 15-deoxy-ll-O-methylspergualin (Ila) was tested and compared with the corresponding racemic compounds (Figs. 2 and 3 ). Six female Slc-CDFi mice (6 weeks old) were inoculated intraperitoneally with 105 cells of L1210 (IMC), a subline of L1210, and the test compoundwas injected intraperitoneally once a day for 6 days starting the day of the tumor inoculation. The antitumor activity was expressed by the T/C (%) value based on meansurvival time at 30 days after the tumor inoculation. The activity of the racemic compound was about 50 %that of the (-)-enantiomer, but the activity of the (+)-enantiomer was about 3 % to 6% of the (-)-enantiomer (Figs. 2 and 3) . The activity of the (+)-enantiomer observed may arise from (-)-enantiomer contaminating the sample. The results showed that the antitumor activity of spergualin and its analogues depended upon the (-)-enantiomer, and that the (+)-enantiomer is virtually inactive. In contrast, all compoundswere acutely toxic at 50 mg/kg/day irrespective of their optical activity. E xp erimental XHNMRspectra were recorded on a Jeol FX-200 (200 MHz)spectrometer. Melting points were measured with a Yanagimoto melting point apparatus, and are uncorrected. Optical rotations were measured with a Jasco DIP-181 digital polarimeter. HPLCwas carried out with a system consisting of an Altex 100A pump, a Shimadzu CTO-2Acolumn oven, a Soma S-310A UVdetector, and a Shimadzu C-R1 B Chromatopac recorder. CPase P was provided by Takara Shuzo Co., Ltd., CPase A, CPase B and CPase Wwere purchased from Sigma Chemical Co., Boehringer Mannheim Yamanouchi Co., and Seikagaku Kogyo Co., Ltd., respectively.
(I) Synthesis of Optically Active 1 5-Deoxy-l l-O-methylspergualin (fla) ( ib )-iV-(7-Guanidinoheptanoyl)-a-hydroxyglycine (VI)
To a solution of 22.3 g (lOO mmol) of 7-guanidinoheptanamide (HC1 salt) in 150 ml of DMF was added 10.2 g (HOmmol) of glyoxylic acid, and the mixture was heated at 70°C for 4 hours. After being cooled, the reaction mixture was evaporated and the residue was dissolved in 100 ml of H2O and chromatographed on a CM-Sephadex C-25 (Na+ form, 1,100-ml) column with elution by H2O. Fractions containing the desired product were combined and evaporated to give 20.9 g (80%) of ( d=)-AL(7-guanidinoheptanoyl)-o:-hydroxyglycine (VI) : MP 1 65 -1 66°C (dec).
( ib )-iV-(7-Guanidmoheptanoyl)-Qf-methoxyglycine (Vila)
To a cooled solution of 9.36 g (36.0 mmol) of VI in MeOH(300 ml) was added 5 ml of concentrated H2SO4,and the mixture was stirred at roomtemp for 3 hours. The reaction mixture was concentrated to 100ml and poured into 200ml of H2O. The pH of the resulting solution was adjusted to 10 with 2 n NaOHand stirred for 1 hour. Then, the pH was adjusted to 6.5 with 2 n HC1 and evaporated. The residue was purified with a CM-Sephadex C-25 (Na+ form) column to give 7.90 g (80%) of (±)-AK7-guanidinoheptanoyl)-tf-methoxyglycine ( The solid, 7.80 g ofVila, was dissolved in 1 n HC1 (28.4 ml) and evaporated to give a white powder of ( ±)-iV-(7-guanidmoheptanoyl)-a-methoxyglycine HC1 salt (Vila). ( =j-)-jV-(7-Guanidinoheptan oyl)-q-methoxyglycyl-L-phenylalanine (Villa) To a solution of 6.58 g (2.21 mmol) of Vila (HC1 salt) and 4.88 g (42.4 mmol) of iV-hydroxysuccinimide in DMF(70 ml) were added 4.87 g (21.2 mmol) of L-phenylalanine ethyl ester (HC1 salt) and 2.98 ml of triethylamine. To the solution was added dropwise a solution of 8.75 g (42.4 mmol) of N,Ar'-dicyclohexylcarbodiimide (DCC) in DMF(30 ml) and the mixture stirred at room temp for 4 hours. The precipitate was filtered off and the filtrate was evaporated. The residue was dissolved in 300 ml of H2Oand chromatographed on a CM-Sephadex C-25 (Na+ form, 1 liter) column by elution with H2Oand a 0.2 m solution of NaCl. Fractions containing the desired product were combined and evaporated. The residue was dissolved in H2Oand chromatographed on a Diaion HP-20 column (1 liter) by successive elution with 1.5 liters of H2O, 2 liters of 25%aq MeOHand 4 liters of 50% aq MeOH.Fractions containing the desired product were combined and evaporated to give 5.3 1 g (51.6 %) of ( ±)-A^-(7-guanidinoheptanoyl)-a:-methoxyglycyl-L-phenylalanine ethyl ester (HC1 salt): *H NMR (CD3OD) 3 1.17 (3H, t, CH3), 1.1-1.9 (8H, m, CH2), 2.27 (2H, t, CH2), 2.9-3.4 (5H), 3.31 (3H, s, OCH3), 4.ll (2H, m, CH2), 5.30 (1H, s, CH), 7.20 (5H, s, C6H5). To a cooled solution of 5.21 g (10.7 mmol) of (±)-iV-(7-guanidinoheptanoyl)-a-methoxyglycyl-Lphenylalanine ethyl ester (HC1 salt) in MeOH(35 ml) was added 12.8 ml 1 n NaOHand the mixture stirred at room temp for 1.5 hours. The reaction mixture was adjusted to pH 6.5 and evaporated to give the calculated amount of (±)-A^-(7-guanidinoheptanoyl)-a-methoxyglycyl-L-phenylalanine (Villa).
( -)-iV-(7-Guanidinoheptanoyl)-q:-methoxyglycine (( -)-IXa)
The residue of Villa was dissolved in 100ml of 0.05 m AcONa-HC1 buffer (pH 5.0). To the solution was added 10 mgof CPase P and the mixture was shaken at 30°C for 8 hours. The reaction mixture was evaporated and the residue was chromatographed on a Sephadex LH-20column (4 liters) by elution with H2O. Fractions containing the desired product were combined and concentrated to 30 ml, adjusted to pH 2.1, and chromatographed on CM-Sephadex C-25 (Na+ form) to give 1.16 g (32.6%) of (-)-iV-(7-guanidinoheptanoyl)-«:-methoxyglycine ( One g (3.65 mmol) of (-)-IXa was dissolved in I n HC1 (3.65 ml), and then the solution was evaporated to dryness to give 1.13 g of (-)-AL(7-guanidinoheptanoyl)-«-methoxyglycine HC1 salt
( 4-)-A^-(7-Guanidinoheptanoyl)-q-methoxyglycine (( + )-IXa) The solid recovered, 1.66 g (3.46 mmol) of (+)-A^-(7-guanidinoheptanoyl)-o:-methoxyglycyl-Lphenylalanine was dissolved in 0.05 m NaHPO4buffer (pH 7.5, 70 ml). To the solution was added 34mgof CPase A and the mixture was stirred at room temp for 9 hours. The reaction mixture was evaporated and the residue was purified with CM-Sephadex C-25 (Na+ form) to give 915 mg (79.5 %) of (+)-iV-(7-guanidinoheptanoyl)-«:-methoxyglycine ( The solid obtained, 900 mg (3.29 mmol) of (+)-IXa, was dissolved in 1 n HC1(3.29 ml) and then evaporated to give 1.00 g of (+)-Ar-(7-guanidinoheptanoyl)-<x-methoxyglycine HC1 salt (( +)-IXa).
To a solution of 709 mg (2.28 mmol) of (-)-Ar-(7-guanidinoheptanoyl)-a:-methoxyglycine (HC1 SEPT. 1987 salt) in DMF(10 ml) were added a solution of 810 mg (4.56 mmol) of iV-2-cyanoethyl-l,4-diaminobutane (mono HC1 salt) in DMF(5 ml) and 524 mg (4.56 mmol) of iV-hydroxysuccinimide. A solution of940 mg ofDCCin DMF(5 ml) was added to the mixture and the solution stirred at room temp overnight. The resulting precipitate was filtered off and the filtrate was diluted with water and washed with EtOAc. The aqueous layer was purified with a CM-Sephadex C-25 (Na+ form, 400-ml) column and a Sephadex LH-20 (500-ml) column to give 599 mg (56%) of ( 
